Acceso usuarios
Enggar Yusrina Hasyyati, Maftuchah Rochmanti, Nafhah Hasan, Adha Fauzi Hendrawan, Arifa Mustika, Happy Kurnia Permatasari, Gioconda Millotti, Fahrul Nurkolis
Background: Melanoma is one of the deadliest forms ofskin cancer, with rising incidence and limited responsivenessto conventional chemotherapy. Marine macroalgae have re-cently emerged as a promising source of novel bioactive com-pounds with potential anticancer properties.
Objective: Thisstudyaimedtoinvestigatetheanticar-cinogenicandantioxidantpotential of Hydropuntia edulis ex-tract (HEE) using integrated metabolomic profiling, in silicopredictions, and in vitro validation against melanoma.
Methods: Untargeted LC-HRMS metabolomic profiling wasconducted to identify bioactive constituents in HEE. Key com-pounds were further analyzed through structure–activity rela-tionship (SAR), ADMET, and molecular docking simulations tar-geting melanoma-related proteins (BRAF, AKT1, EGFR, andTYRO3). Antioxidant and antiproliferative effects were assessedusing DPPH and MTT assays on B16-F10 melanoma cells.
Results: Several metabolites including Sangivamycin,Michosterol C, Linamarin, and Elaiomycin K were identified.SAR analysis showed high antineoplastic probability forLinamarin (Pa = 0.831), Sangivamycin (Pa = 0.730), andMichosterol C (Pa = 0.759). Michosterol C showed strongbinding affinity to BRAF (−9.2 kcal/mol), comparable toDabrafenib (−9.1 kcal/mol). HEE demonstrated dose-depen-dent DPPH radical scavenging and inhibited melanoma cellproliferation with IC50 values similar to positive controls Conclusion: This study highlights Hydropuntia edulis as apromising source of nutraceutical agents against melanoma.Through a combination of metabolomic profiling, computationalprediction, and in vitro testing, HEE was shown to contain mul-tiple bioactive compounds with antioxidant and antiproliferativepotential. These findings suggest HEE could be further devel-oped as a dietary supplement or functional food to support nu-tritional management of melanoma patients, rather than as astand-alone chemotherapeutic. Future studies including com-pound isolation, in vivo validation, and clinical trials are neededto clarify its relevance, optimal dosing, and safety profile
